All Articles
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia. Read More ›
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact. Read More ›
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features. Read More ›
By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them. Read More ›
By Priya Kalra
In this heartfelt poem, Priya Kalra writes about riding the challenging waves of emotions after being diagnosed with breast cancer in December 2017. Read More ›
Speech-language pathologist Stacey Brill, MS, CCC-SLP, shares her journey by her mom’s side as she battled cancer, and the subsequent care and services she had provided to many patients with cancer, in her mom’s memory. Read More ›
In May 2021, the FDA approved Rybrevant (amivantamab-vmjw), an intravenous antibody that targets mutations in the EGFR and MET pathways, for the treatment of adults with non–small-cell lung cancer and EGFR exon 20 insertion mutations. This is the first drug approved for lung cancer with EGFR exon 20 insertion mutations. Read More ›
In May 2021, the FDA approved Lumakras (sotorasib), an oral KRAS inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer associated with KRAS G12C mutation. Lumakras is the first drug approved for any cancer associated with any KRAS mutation. Read More ›
In April 2021, the FDA approved Zynlonta (loncastuximab tesirine), the first CD19-directed antibody–drug conjugate, for the treatment of patients with relapsed or refractory large B-cell lymphoma. Read More ›